Goldman Sachs
ALXN

Goldman Sachs’s Alexion Pharmaceuticals ALXN Stock Holding History

Goldman Sachs’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,000
Closed -$3.21M – 6781
2021
Q1 		$3.21M Sell
21,000
-46,100
-69% -$7.13M ﹤0.01% 3536
2020
Q4 		$10.5M Buy
67,100
+45,000
+204% +$5.78M ﹤0.01% 2418
2020
Q3 		$2.53M Sell
22,100
-8,000
-27% -$863K ﹤0.01% 3403
2020
Q2 		$3.38M Sell
30,100
-46,600
-61% -$4.95M ﹤0.01% 3075
2020
Q1 		$6.89M Buy
76,700
+66,700
+667% +$6.55M ﹤0.01% 2384
2019
Q4 		$1.08M Sell
10,000
-5,000
-33% -$535K ﹤0.01% 4079
2019
Q3 		$1.47M Sell
15,000
-400
-3% -$45.1K ﹤0.01% 3763
2019
Q2 		$2.02M Sell
15,400
-31,800
-67% -$4.1M ﹤0.01% 3552
2019
Q1 		$6.38M Buy
+47,200
New +$5.87M ﹤0.01% 2780
2018
Q4 		– Sell
-1,000
Closed -$139K – 5845
2018
Q3 		$139K Hold
1,000
– – ﹤0.01% 5029
2018
Q2 		$124K Sell
1,000
-1,500
-60% -$175K ﹤0.01% 5151
2018
Q1 		$279K Sell
2,500
-57,200
-96% -$6.84M ﹤0.01% 4821
2017
Q4 		$7.14M Sell
59,700
-81,800
-58% -$9.96M ﹤0.01% 2709
2017
Q3 		$19.9M Sell
141,500
-6,600
-4% -$897K ﹤0.01% 1996
2017
Q2 		$18M Buy
148,100
+36,100
+32% +$4.2M ﹤0.01% 2017
2017
Q1 		$13.6M Buy
112,000
+7,400
+7% +$954K ﹤0.01% 2181
2016
Q4 		$12.8M Sell
104,600
-4,200
-4% -$514K ﹤0.01% 2272
2016
Q3 		$13.3M Buy
108,800
+61,100
+128% +$7.86M ﹤0.01% 2222
2016
Q2 		$5.57M Sell
47,700
-168,200
-78% -$23.9M ﹤0.01% 2772
2016
Q1 		$30.1M Buy
215,900
+187,400
+658% +$27.5M 0.01% 1422
2015
Q4 		$5.44M Sell
28,500
-46,400
-62% -$8.11M ﹤0.01% 2742
2015
Q3 		$11.7M Buy
74,900
+22,185
+42% +$4.05M ﹤0.01% 2125
2015
Q2 		$9.53M Sell
52,715
-24,185
-31% -$4.17M ﹤0.01% 2368
2015
Q1 		$13.3M Buy
76,900
+6,100
+9% +$1.1M ﹤0.01% 2063
2014
Q4 		$13.1M Buy
70,800
+11,500
+19% +$2.13M ﹤0.01% 2138
2014
Q3 		$9.83M Buy
59,300
+27,100
+84% +$4.45M ﹤0.01% 2381
2014
Q2 		$5.03M Sell
32,200
-118,600
-79% -$18.7M ﹤0.01% 3028
2014
Q1 		$22.9M Buy
150,800
+58,200
+63% +$9.25M 0.01% 1655
2013
Q4 		$12.3M Sell
92,600
-10,900
-11% -$1.31M ﹤0.01% 2182
2013
Q3 		$12M Buy
103,500
+1,100
+1% +$121K ﹤0.01% 2068
2013
Q2 		$9.45M Buy
+102,400
New +$9.87M ﹤0.01% 2148

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Goldman Sachs's ALXN Position: Q3 2021 in Review

Goldman Sachs sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 781,412 shares — an estimated $144M sold.

Goldman Sachs first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $584M in Q2 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Goldman Sachs reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 781,412 Alexion Pharmaceuticals shares in Q3 2021, an estimated $144M.
  • Goldman Sachs first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Goldman Sachs's Alexion Pharmaceuticals position peaked at $584M in Q2 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.